In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 19.5 above Palisade Bio Inc average.

Within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Quick Ratio than Palisade Bio Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 109 to 185.

Explain Quick Ratio?
How much Cash & cash equivalents PALI�s has?
What are PALI�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PALI/financial-strength

https://api.csimarket.com/api/v1/companies/PALI/fundamentals

https://api.csimarket.com/api/v1/companies/PALI/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

PALI Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	67.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	2073.58 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	19.5	Subscribe	Subscribe	Subscribe	Subscribe
PALI's Total Ranking	# 185	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	11.06 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-9.23 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 9
Healthcare Sector	# 40
Overall Market	# 185

Quick Ratio Statistics
High	Average	Low
168.29	15.09	0.22
(Jun 30 2017)		(Dec 31 2020)

Financial Statements
Palisade Bio Inc 's Current Liabilities	$ 6 Millions	Visit PALI's Balance sheet
Palisade Bio Inc 's Cash & cash equivalent	$ 114 Millions	Visit PALI's Balance sheet
Source of PALI's Sales		Visit PALI's Sales by Geography

Cumulative Palisade Bio Inc 's Quick Ratio

PALI's Quick Ratio for the trailling 12 Months

PALI Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	59.13 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	1722.7 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	23.67	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 83	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	12.37 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	27.34 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to PALI Financial Strength Comparisons >> Go to Compare PALI Quick Ratio to its Competitors

On the trailing twelve months basis PALI Cash & cash equivalent more than doubled by 2073.58 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Palisade Bio Inc 's Quick Ratio to 23.67, above PALI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 127 other companies have achieved higher Quick Ratio than Palisade Bio Inc . While Quick Ratio overall ranking has improved so far to 2778, from total ranking during the twelve months ending second quarter 2026 at 3073.

Explain Quick Ratio?
How much Cash & cash equivalents PALI�s has?
What are PALI�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 128
Healthcare Sector	# 776
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
23.67	4.37	0.33
(Sep 30 2026)		(Mar 31 2021)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Hemab Therapeutics Holdings Inc	33.25	$ 430.238 Millions	$ 12.940 Millions
Artiva Biotherapeutics Inc	19.52	$ 320.347 Millions	$ 16.408 Millions
Palisade Bio Inc	19.50	$ 113.613 Millions	$ 5.826 Millions
Taysha Gene Therapies Inc	18.42	$ 422.834 Millions	$ 22.950 Millions
Crispr Therapeutics Ag	16.12	$ 2,272.548 Millions	$ 140.962 Millions
Imagenebio Inc	15.68	$ 126.597 Millions	$ 8.075 Millions
Inhibikase Therapeutics Inc	14.92	$ 193.321 Millions	$ 12.957 Millions
Aura Biosciences Inc	13.93	$ 297.233 Millions	$ 21.337 Millions
Maze Therapeutics Inc	13.77	$ 389.658 Millions	$ 28.300 Millions
Vor Biopharma Inc	13.25	$ 481.551 Millions	$ 36.344 Millions
Tectonic Therapeutic Inc	13.05	$ 234.666 Millions	$ 17.986 Millions
Beam Therapeutics Inc	12.72	$ 1,043.873 Millions	$ 82.076 Millions
X4 Pharmaceuticals Inc	12.53	$ 187.701 Millions	$ 14.984 Millions
Odyssey Therapeutics, Inc.	12.49	$ 326.001 Millions	$ 26.101 Millions
Solid Biosciences Inc	11.46	$ 348.928 Millions	$ 30.454 Millions
Kalaris Therapeutics Inc	9.73	$ 82.856 Millions	$ 8.514 Millions
Zura Bio Limited	9.22	$ 187.652 Millions	$ 20.349 Millions
Scribe Therapeutics, Inc.	9.19	$ 348.383 Millions	$ 37.928 Millions
Protara Therapeutics Inc	8.83	$ 127.050 Millions	$ 14.391 Millions
Cardiff Oncology Inc	8.57	$ 71.286 Millions	$ 8.316 Millions
Candel Therapeutics Inc	7.42	$ 203.116 Millions	$ 27.388 Millions
4d Molecular Therapeutics Inc	7.16	$ 375.033 Millions	$ 52.394 Millions
Immunovant Inc	6.94	$ 722.274 Millions	$ 104.022 Millions
Repligen Corp	6.87	$ 862.979 Millions	$ 125.686 Millions
Kyverna Therapeutics Inc	6.79	$ 170.572 Millions	$ 25.136 Millions
Compass Therapeutics Inc	6.69	$ 163.058 Millions	$ 24.368 Millions
Black Diamond Therapeutics Inc	6.62	$ 102.030 Millions	$ 15.405 Millions
Krystal Biotech Inc	6.45	$ 916.484 Millions	$ 142.144 Millions
Voyager Therapeutics Inc	6.35	$ 106.806 Millions	$ 16.813 Millions
Cabaletta Bio Inc	6.33	$ 299.383 Millions	$ 47.332 Millions

Date modified: 2026-11-11T05:56:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.